Panna Sharma - Lantern Pharma CEO President
| LTRN Stock | USD 5.01 0.18 3.73% |
CEO
Panna Sharma is CEO President of Lantern Pharma
| Age | 54 |
| Phone | 972 277 1136 |
| Web | https://www.lanternpharma.com |
Lantern Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3394) % which means that it has lost $0.3394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5303) %, meaning that it created substantial loss on money invested by shareholders. Lantern Pharma's management efficiency ratios could be used to measure how well Lantern Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CEO Age | ||
| MSc JD | Cue Biopharma | 64 | |
| Maria Palasis | Lyra Therapeutics | 59 | |
| Clay Siegall | Immunome | 64 | |
Management Performance
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.34 |
Lantern Pharma Leadership Team
Elected by the shareholders, the Lantern Pharma's board of directors comprises two types of representatives: Lantern Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lantern. The board's role is to monitor Lantern Pharma's management team and ensure that shareholders' interests are well served. Lantern Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lantern Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| DVM MS, CoFounder Advisor | ||
| Nicole Leber, Finance Associate | ||
| MS BS, Head Operations | ||
| Kishor Bhatia, Chief Consultant | ||
| Marc MD, Chief Therapeutics | ||
| Panna Sharma, CEO President | ||
| David Margrave, CFO Secretary |
Lantern Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lantern Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 26.27 M | ||||
| Shares Outstanding | 10.78 M | ||||
| Shares Owned By Insiders | 14.71 % | ||||
| Shares Owned By Institutions | 35.05 % | ||||
| Number Of Shares Shorted | 238.67 K | ||||
| Price To Book | 2.03 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (15.96 M) |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.